Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Asciminib + Dasatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Asciminib||Scemblix||ABL001|ABL-001||BCR-ABL Inhibitor 28||Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov).|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 28 BTK inhibitor 32 CSF1R Inhibitor 26 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 53 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 31 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02081378||Phase I||Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib||A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL||Active, not recruiting||USA | ITA | FRA | ESP | DEU||5|
|NCT03906292||Phase II||Asciminib + Nilotinib Asciminib + Imatinib Asciminib + Dasatinib||Frontline Asciminib Combination in Chronic Phase CML (CMLXI)||Active, not recruiting||DEU||0|